Delivery Order SPE2DB20D3101-SPE2DB24FRWC5

Award Date 9/24/24
Potential Completion Date 10/16/24
Potential Value $1.8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is a delivery order with a firm fixed price and a ceiling value of $1,859.50. The contract is not set aside and will deliver ZOLADEX 10.8 MG IMPLANT SYRNS to the government. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award, valued at $5,263.74, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of ZOLADEX 10.8 MG IMPLANT SYRNS, with a completion date of March 15, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,323.88 firm fixed-price delivery order is for ZOLADEX 3.6 MG IMPLANT SYRNS, a specialty pharmaceutical product. The contract has an ultimate completion date of April 22, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The contract has a ceiling value of $5,263.74 and is for the delivery of 4564821326 units of the pharmaceutical product ZOLADEX 10.8 MG IMPLANT SYRNS. The contract is a Delivery Order with a Firm Fixed Price pricing type, and the ultimate completion date is June 26, 2024. Amerisourcebergen Drug Corp, a major supplier of pharmaceutical products and medical...
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract worth $3,509.16 to Amerisourcebergen Drug Corp's Corporate Office Division, a major supplier of pharmaceutical products and medical supplies to the federal government. The contract is for the delivery of ZOLADEX 10.8 MG IMPLANT SYRNS, with a completion date of June 13, 2024. This award is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, provides $7,018.24 in Firm Fixed Price funding for a delivery order to supply the Defense Logistics Agency (DLA) with ZOLADEX 10.8 MG IMPLANT SYRNS, a specialty medication. The award has no set-aside designation and is scheduled for completion by September 17, 2024. Amerisourcebergen holds several significant Indefinite Delivery Contracts (IDCs) with the DLA and other federal agencies, valued up to...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, Corporate Office Division, a major pharmaceutical distributor. The contract, valued at $1,249.20, is a Firm Fixed Price Delivery Order for the supply of ZOLADEX 3.6 MG IMPLANT SYRNS, a cancer medication. The contract has an ultimate completion date of October 2, 2024. Amerisourcebergen, as one of the largest pharmaceutical distributors in the United States, leverages its extensive...
This is a federal contract award by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the delivery of 4,565,606,804 units of the pharmaceutical product ZOLADEX 10.8 MG IMPLANT SYRNS. The contract has a firm fixed price ceiling value of $1,754.58 and an ultimate completion date of September 17, 2024. AmerisourceBergen, a major supplier of pharmaceutical products and medical supplies to the U.S. government, has been awarded this delivery order contract without any set-aside...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,938.54, is a Firm Fixed Price Delivery Order for the supply of ZOLADEX 3.6 MG IMPLANT SYRNS, a pharmaceutical product. The contract has an ultimate completion date of January 17, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award, valued at $2,379.18, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office Division. The contract is for the delivery of 4,565,607,277 ZOLADEX 10.8 MG IMPLANT SYRNS, a pharmaceutical product. The contract has a firm fixed price and a period of performance through September 17, 2024. AmerisourceBergen, as a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, has been awarded...
  • SPE2DB20D3101
    Indefinite Delivery Contract
  • SPE2DB20D3101-SPE2DB24FRWC5
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,754.58 firm-fixed-price delivery order is for the supply of ZOLADEX 10.8 MG IMPLANT SYRNS, a specialty medication. The contract has an ultimate completion date of October 16, 2024.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, covering similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies for military personnel, veterans, and other federal beneficiaries.

Generated 2/27/25, 11:50 AM